1. Home
  2. MEGL vs REVB Comparison

MEGL vs REVB Comparison

Compare MEGL & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Empire Global Limited

MEGL

Magic Empire Global Limited

HOLD

Current Price

$1.35

Market Cap

5.1M

Sector

Finance

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.97

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEGL
REVB
Founded
2016
2020
Country
Hong Kong
United States
Employees
N/A
9
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
MEGL
REVB
Price
$1.35
$0.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.4K
38.2K
Earning Date
04-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.47
52 Week High
$2.27
$3.21

Technical Indicators

Market Signals
Indicator
MEGL
REVB
Relative Strength Index (RSI) 61.10 37.26
Support Level $1.16 $0.85
Resistance Level $1.39 $1.40
Average True Range (ATR) 0.11 0.05
MACD 0.02 -0.00
Stochastic Oscillator 58.83 11.87

Price Performance

Historical Comparison
MEGL
REVB

About MEGL Magic Empire Global Limited

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: